Monopar Therapeutics Inc (MNPR) has issued an announcement.
Monopar Therapeutics Inc. has announced the milestone achievement of successfully administering their uPAR-targeted imaging radiopharmaceutical, MNPR-101-Zr, to the first patient in an open-label Phase 1 clinical trial. This marks a significant step forward in their efforts to advance this innovative diagnostic tool in the medical field.
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.
